VNP40101M in Treating Patients With Advanced or Metastatic Cancer
A Phase I Trial of VNP40101M, a Novel Alkylating Agent, Administered Weekly for Patients With Advanced or Metastatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
PURPOSE: Phase I trial to study the effectiveness of VNP40101M in treating patients who have advanced or metastatic cancer.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
OBJECTIVES:
- Determine the toxic effects of VNP40101M in patients with advanced or metastatic solid tumor or lymphoma.
- Determine the maximum tolerated dose of this drug in these patients.
- Determine the pharmacokinetics of this drug in these patients.
- Determine the antitumor effects of this drug in these patients.
OUTLINE: This is a dose-escalation study.
Patients receive VNP40101M IV over 15 minutes on days 1, 8, and 15. Treatment repeats every 28 days.
Cohorts of 3-6 patients receive escalating doses of VNP40101M until the maximum tolerated dose is determined.
PROJECTED ACCRUAL: Approximately 20 patients will be accrued for this study.
Undersøgelsestype
Undersøgelsestype
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
Connecticut
-
New Haven, Connecticut, Forenede Stater, 06520-8028
- Yale Comprehensive Cancer Center
-
West Haven, Connecticut, Forenede Stater, 06516
- Veterans Affairs Medical Center - West Haven
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44106-5065
- Ireland Cancer Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
DISEASE CHARACTERISTICS:
- Histologically confirmed advanced or metastatic solid tumor or lymphoma for which no curative or standard effective therapy exists
- Measurable or evaluable disease
- Primary brain tumors or brain metastases allowed provided neurologic deficits are stable and do not preclude study compliance
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- ECOG 0-1
Life expectancy
- At least 3 months
Hematopoietic
- Granulocyte count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
- Hematocrit at least 30% (transfusion allowed)
- No bleeding diathesis
Hepatic
- PT and PTT no greater than 1.5 times the upper limit of normal (ULN)
- Bilirubin no greater than 1.5 times ULN
- ALT and AST no greater than 1.5 times ULN (3 times ULN if liver metastases present)
- Albumin at least 2.5 gm/dL
Renal
- Creatinine no greater than 2.0 mg/dL
Cardiovascular
- At least 3 months since prior myocardial infarction
- No symptomatic coronary artery disease
- No arrhythmias requiring medication
- No uncontrolled congestive heart failure
Pulmonary
- No dyspnea on minimal or moderate exertion
- DLCO and FEV1 at least 60% predicted
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No uncontrolled active bleeding (e.g., active peptic ulcer disease)
- No active infection
- HIV negative
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Recovered from acute toxicities of prior biologic therapy (persisting, chronic toxicity allowed if stable and no greater than grade 1)
Chemotherapy
- More than 6 months since prior high-dose chemotherapy with stem cell support
- More than 3 weeks since prior cytotoxic chemotherapy (6 weeks for mitomycin or nitrosoureas)
- Recovered from acute toxicities of prior chemotherapy (persisting, chronic toxicity allowed if stable and no greater than grade 1)
Endocrine therapy
- At least 2 weeks since prior hormonal therapy
Radiotherapy
- Recovered from acute toxicities of prior radiotherapy (persisting, chronic toxicity allowed if stable and no greater than grade 1)
Surgery
- At least 2 weeks since prior surgery
Other
- No other concurrent standard or investigational treatment for cancer
- No concurrent disulfiram
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart
Studiestart
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
- uspecificeret voksen solid tumor, protokol specifik
- stadium IV grad 3 follikulært lymfom
- stadium IV voksent diffust storcellet lymfom
- stadium IV voksen immunoblastisk storcellet lymfom
- stadium IV voksen Burkitt lymfom
- tilbagevendende grad 3 follikulært lymfom
- tilbagevendende voksent diffust storcellet lymfom
- tilbagevendende voksen immunoblastisk storcellet lymfom
- recidiverende voksen Burkitt lymfom
- recidiverende voksen Hodgkin lymfom
- recidiverende voksent diffust små spaltet celle lymfom
- recidiverende voksent diffust blandet celle lymfom
- stadium IV grad 1 follikulært lymfom
- stadium IV grad 2 follikulært lymfom
- stadium IV voksent diffust små spaltet celle lymfom
- stadium IV voksent diffust blandet celle lymfom
- stadium IV mantelcellelymfom
- tilbagevendende grad 1 follikulært lymfom
- tilbagevendende grad 2 follikulært lymfom
- tilbagevendende marginal zone lymfom
- tilbagevendende lille lymfocytisk lymfom
- stadium IV lille lymfocytisk lymfom
- stadium IV marginal zone lymfom
- ekstranodal marginal zone B-celle lymfom af slimhinde-associeret lymfoid væv
- nodal marginal zone B-celle lymfom
- milt marginal zone lymfom
- tilbagevendende lymfoblastisk lymfom hos voksne
- tilbagevendende kappecellelymfom
- primært non-Hodgkin lymfom i centralnervesystemet
- stadium IV voksen Hodgkin lymfom
- stadium IV kutant T-celle non-Hodgkin lymfom
- tilbagevendende kutant T-celle non-Hodgkin lymfom
- tyndtarms lymfom
- stadium IV voksen lymfoblastisk lymfom
- stadium IV voksen T-celle leukæmi/lymfom
- tilbagevendende voksen T-celle leukæmi/lymfom
- intraokulært lymfom
- angioimmunoblastisk T-celle lymfom
- anaplastisk storcellet lymfom
- stadium IV mycosis fungoides/Sezary syndrom
- tilbagevendende mycosis fungoides/Sezary syndrom
Yderligere relevante MeSH-vilkår
- Sygdomme i fordøjelsessystemet
- Patologiske processer
- Sygdomme i immunsystemet
- Neoplasmer efter histologisk type
- Neoplasmer
- Lymfoproliferative lidelser
- Lymfesygdomme
- Immunproliferative lidelser
- Neoplasmer efter sted
- Gastrointestinale neoplasmer
- Neoplasmer i fordøjelsessystemet
- Gastrointestinale sygdomme
- Tarmsygdomme
- Neoplastiske processer
- Lymfom
- Neoplasma Metastase
- Intestinale neoplasmer
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- VION-CLI-028
- CDR0000258355 (Registry Identifier: PDQ (Physician Data Query))
- YALE-HIC-16775
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .